Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
891.1 USD | -0.16% | -0.85% | +1.62% |
04-26 | Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says | MT |
04-26 | Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.62% | 96.29B | |
-2.63% | 102B | |
+1.51% | 22.18B | |
-16.67% | 21.2B | |
-9.63% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B | |
+305.27% | 8.32B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals : SVB Leerink Adjusts Regeneron Pharmaceuticals' Price Target to $653 from $650, Maintains Outperform Rating